High Serum Levels of IL-6 Predict Poor Responses in Patients Treated with Pembrolizumab plus Axitinib for Advanced Renal Cell Carcinoma

SIMPLE SUMMARY: Renal cell carcinoma (RCC) is one of the most common types of cancers concerning the kidneys worldwide. Pembrolizumab and axitinib treatment (Pembro/Axi) is amongst the most effective first-line immunotherapies for advanced RCC. However, it remains difficult to predict the effectiven...

Descripción completa

Detalles Bibliográficos
Autores principales: Sang, Yun Beom, Yang, Hannah, Lee, Won Suk, Lee, Seung Joon, Kim, Seul-Gi, Cheon, Jaekyung, Kang, Beodeul, Kim, Chang Woo, Chon, Hong Jae, Kim, Chan
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9738341/
https://www.ncbi.nlm.nih.gov/pubmed/36497467
http://dx.doi.org/10.3390/cancers14235985

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9738341/
https://www.ncbi.nlm.nih.gov/pubmed/36497467
http://dx.doi.org/10.3390/cancers14235985

Ejemplares similares